The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the ...

Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have ...

Compass shares are trading at $5.89, near their 52-week high of $6.88 and well above the $1.33 low touched last year. Recent analyst activity underscores the bullish sentiment. Craig-Hallum initiated ...